Bristol-Myers Squibb (BMY) to Release Earnings on Thursday

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, April 24th. Analysts expect Bristol-Myers Squibb to post earnings of $1.55 per share and revenue of $10.77 billion for the quarter. Bristol-Myers Squibb has set its FY 2025 guidance at 6.550-6.850 EPS.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. On average, analysts expect Bristol-Myers Squibb to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol-Myers Squibb Price Performance

BMY traded up $0.88 during trading on Tuesday, reaching $49.82. 13,269,095 shares of the company traded hands, compared to its average volume of 12,999,573. The company has a market cap of $101.37 billion, a P/E ratio of -11.27, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The firm has a fifty day simple moving average of $56.71 and a 200 day simple moving average of $56.59.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.98%. Bristol-Myers Squibb's payout ratio is -56.11%.

Wall Street Analyst Weigh In

Several research analysts have commented on BMY shares. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday. They set an "overweight" rating and a $65.00 price objective for the company. UBS Group dropped their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Truist Financial lifted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $58.13.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The shares were acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.09% of the company's stock.

Institutional Trading of Bristol-Myers Squibb

An institutional investor recently raised its position in Bristol-Myers Squibb stock. Brighton Jones LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 33.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,728 shares of the biopharmaceutical company's stock after purchasing an additional 4,935 shares during the quarter. Brighton Jones LLC's holdings in Bristol-Myers Squibb were worth $1,116,000 as of its most recent filing with the Securities & Exchange Commission. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.